CompletedHealthcare13 February 2023

Cytek Biosciences, Inc. to acquire Luminex Corporation

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Cytek Biosciences, Inc.
Target
Luminex Corporation
Deal value
USD 46,500,000
Announced
13 February 2023
Status
Completed
Sector
Healthcare
Country
United States
Consideration
cash
What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update
  1. CompletedClosed

    Cytek Biosciences, Inc. completes acquisition of Luminex Corporation

    Item 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed in the Current Report on Form 8-K filed by Cytek Biosciences, Inc. (the “Company”) on February 13, 2023, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company acquired certain assets relating to the flow cytometry and ima

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer
Public Company Management Corporation
Target
Physicians Capital Management Corporation
Deal value
Not disclosed
Deal type
strategic acquisition

Buyer history

Cytek Biosciences, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive